The Rohatyn Group Completes Investment in Innovative Pet Accessories Company, MyFamily
11.3.2021 21:24:00 EET | Business Wire | Press release
The Rohatyn Group (“TRG”), a global, US-based asset management firm, today announced that it has completed an investment in the specialized pet accessories company MyFamily Srl (“MyFamily” or the “Company”), establishing a partnership with the Company’s founder, Alessandro Borgese, and existing investors including 035 investimenti S.p.A. TRG’s investment will allow MyFamily to accelerate its product rollout and continue expanding its global distribution channels. Terms of the transaction were not disclosed.
Founded in 2011 in Valenza, Italy, MyFamily is a global producer of engravable pet ID tags and tag engraving machines. The Company’s engraving machines are present in approximately 9,000 retail locations in more than 70 countries worldwide. The Company has recently expanded its pet accessories assortment through a unique range of pet collars, leashes and harnesses, including the technology-enabled Memopet collection, which offers a differentiated smart and interactive experience.
“MyFamily is a highly attractive business that provides a unique product offering in the global pet accessories sector. We believe the Company is well positioned to benefit from accelerated premiumization of pet products and deliver strong growth as the global pet accessories market continues to expand,” said TRG’s Colin Clark, Head of the EMEA Private Markets investment team, and Stepan Karpukhin, Managing Director.
TRG’s Harold Chatelus, who will immediately join the Board of Directors of MyFamily, added, “Alessandro Borgese leads a highly qualified and motivated global management team, whose dedication to product innovation is evident in the quality and design leadership of MyFamily’s product portfolio. TRG will actively support the Company’s expansion strategy with the goal of enhancing scale and solidifying global market leadership.”
Nick Rohatyn, CEO of TRG added, “MyFamily is a high-growth business with international access that fits in perfectly with TRG’s global approach. We believe strongly that the Company has the potential to transform the global pet accessories sector thanks to its innovative and technology-forward strategy. Our investment team will seek to leverage our deep knowledge of the pet care industry and positive experience from current portfolio company Pet Network International to assist Alessandro and his talented team in achieving their growth objectives.”
Alessandro Borgese, founder and CEO of MyFamily, commented, “I am tremendously proud of the growth MyFamily has already achieved, particularly over the last two years, as we have transformed our product portfolio, invested greatly in production quality and automation, and expanded our distribution network following the launch of our US subsidiary. TRG’s investment will accelerate the next phase in MyFamily’s development. We look forward to continuing our growth in partnership with The Rohatyn Group and leveraging the team’s expertise.”
About TRG
Founded in 2002, The Rohatyn Group is an emerging markets focused asset management firm headquartered in New York, with a presence around the globe including Boston, Buenos Aires, Montevideo, Lima, São Paulo, San Jose, London, Cairo, Mumbai, New Delhi, Singapore, Hanoi, Kuala Lumpur and Rotorua. For more information, please visit www.rohatyngroup.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210311005900/en/
Contact information
Julie Rudnick / Columbia Clancy
Sard Verbinnen & Co
(212) 687-8080
JRudnick@SARDVERB.COM / CClancy@SARDVERB.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufacturing site. All other aspects of the BLA, including safety- and efficacy-related parts, did not solicit deficiencies to be addressed. The FDA made observations during the PLI for which Galderma is putting in place corrective and preventive actions. Galderma will also be seeking further guidance through continued open dialogue with the FDA toward resolution of the relevant observations. Galderma plans to rapidly respond to the CRL and advancing RelabotulinumtoxinA in the U.S. remains a top priority. The ob
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 04:45:00 EEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom